Cambendazole in the treatment of human strongyloidiasis.
Cambendazole was used for the treatment of strongyloidiasis in 40 hospitalized patients, given in a single dose of 5 mg/kg body weight. According to the criteria adopted, parasitological cure was obtained in 100% of cases. Side effects were negligible, and did not require interruption of treatment. We therefore conclude that cambendazole is at present the most effective agent for the therapy of human strongyloidiasis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001562:Benzimidazoles / Q000627:therapeutic use*; D002159:Cambendazole / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013322:Strongyloidiasis / Q000188:drug therapy*
D001562:Benzimidazoles; D002159:Cambendazole